Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Operating Expenses (2020 - 2025)

Insight Molecular Diagnostics' Operating Expenses history spans 6 years, with the latest figure at $11.2 million for Q3 2025.

  • For Q3 2025, Operating Expenses fell 17.53% year-over-year to $11.2 million; the TTM value through Sep 2025 reached $63.7 million, up 46.09%, while the annual FY2024 figure was $61.8 million, 141.81% up from the prior year.
  • Operating Expenses for Q3 2025 was $11.2 million at Insight Molecular Diagnostics, up from $10.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $34.2 million in Q4 2024 and bottomed at -$5.8 million in Q1 2023.
  • The 5-year median for Operating Expenses is $10.2 million (2025), against an average of $10.0 million.
  • The largest YoY upside for Operating Expenses was 416.96% in 2023 against a maximum downside of 278.92% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $17.8 million in 2021, then plummeted by 34.69% to $11.6 million in 2022, then soared by 38.22% to $16.1 million in 2023, then skyrocketed by 113.06% to $34.2 million in 2024, then crashed by 67.31% to $11.2 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Operating Expenses are $11.2 million (Q3 2025), $10.2 million (Q2 2025), and $8.1 million (Q1 2025).